{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:26:26Z","timestamp":1777044386114,"version":"3.51.4"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Implantable cardioverter-defibrillators (ICDs) reduce the risk of sudden cardiac death caused by ventricular tachycardia or ventricular fibrillation in patients with ischemic and non-ischemic cardiomyopathy. However, the cost-effectiveness of ICD implantation in Japanese patients with heart failure and reduced left ventricular ejection fraction remains unclear. This study aimed to evaluate the cost-effectiveness of ICD implantation in a Japanese setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model with 1-month cycles was developed to assess the cost-effectiveness of ICD implantation compared with conventional medical therapy. The analysis was conducted from the perspective of a public healthcare payer over a 30-year time horizon. Scenario analyses accounting for waning treatment effects were performed, as along with deterministic and probabilistic sensitivity analyses (PSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base-case analysis, the incremental cost-effectiveness ratio (ICER) was US $29,838 per quality-adjusted life year (QALY). In the scenario analyses, the ICER increased to US $40,205 and $36,199 per QALY when the treatment effect began to wane after 5 and 10 years, respectively. ICD efficacy and battery longevity had the greatest influence on the ICER. PSA showed that the ICER per QALY ranged from US $19,472 at the 2.5th percentile to US $83,365 at the 97.5th percentile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the Japanese healthcare context, ICD implantation for primary prevention was found to be more cost-effective than the reference value. However, depending on several assumptions, the ICER may exceed the reference value. Sensitivity analyses highlighted the significant impact of the hazard ratio and battery longevity on cost-effectiveness. Further research is needed to identify subpopulations with significantly different cost-effectiveness outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1744517","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:26:08Z","timestamp":1772688368000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention in heart failure with reduced ejection fraction: a Markov model using JROAD-DPC cost data in Japan"],"prefix":"10.3389","volume":"13","author":[{"given":"Kazuki","family":"Ohashi","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, Hokkaido University","place":["Sapporo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Caress Memorial Hospital","place":["Sapporo, Japan"]},{"name":"Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine","place":["Sapporo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Morii","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Hokkaido University","place":["Sapporo, Japan"]},{"name":"Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health","place":["Wako, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Yokoshiki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Sapporo City General Hospital","place":["Sapporo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Kusano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center Hospital","place":["Suita, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Kure Medical Center","place":["Kure, Japan"]},{"name":"Cardiovascular Surgery, Hiroshima University","place":["Hiroshima, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Takagi","sequence":"additional","affiliation":[{"name":"Division of Cardiac Arrhythmia, Kansai Medical University Medical Centre","place":["Moriguchi, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teiichi","family":"Yamane","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Jikei University School of Medicine","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Hokkaido University","place":["Sapporo, Japan"]},{"name":"Faculty of Engineering, Muroran Institute of Technology","place":["Muroran, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102198","DOI":"10.1016\/j.cpcardiol.2023.102198","article-title":"Implantable cardioverter defibrillators for primary prevention in patients with ischemic and non-ischemic cardiomyopathy: a meta-analysis","volume":"49","author":"Jaiswal","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.jacc.2024.11.023","article-title":"ACC\/AHA\/ASE\/HFSA\/HRS\/SCAI\/SCCT\/SCMR 2025 appropriate use criteria for implantable cardioverter-defibrillators, cardiac resynchronization therapy, and pacing","volume":"85","author":"Russo","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e70033","DOI":"10.1002\/joa3.70033","article-title":"JCS\/JHRS 2024 guideline focused update on management of cardiac arrhythmias","volume":"41","author":"Iwasaki","year":"2025","journal-title":"J Arrhythm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/europace\/eup068","article-title":"Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population","volume":"11","author":"Cowie","year":"2009","journal-title":"Europace"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0241697","DOI":"10.1371\/journal.pone.0241697","article-title":"Implantable cardioverter defibrillator therapy is cost effective for primary prevention patients in Taiwan: an analysis from the improve SCA trial","volume":"15","author":"Holbrook","year":"2020","journal-title":"PLoS One"},{"key":"B7","first-page":"1","volume-title":"Implantable Cardioverter Defibrillators and Cardiac Resynchronisation Therapy for Arrhythmias and Heart Failure (TA314)","year":"2014"},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10916-007-9107-7","article-title":"Cost-effectiveness of implantable cardioverter-defibrillators in Brugada syndrome treatment","volume":"32","author":"Wang","year":"2008","journal-title":"J Med Syst"},{"key":"B9","article-title":"Revision of medical fees for FY2024","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/jce.16150","article-title":"The clinical and economic impact of extended battery longevity of a substernal extravascular implantable cardioverter defibrillator","volume":"35","author":"Knight","year":"2024","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B11","article-title":"Number of ICDs and CRT-Ds implanted by prefecture","year":"2025"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1253\/circj.CJ-23-0613","article-title":"Two-year outcomes of primary prophylactic use of defibrillators for ischemic and non-ischemic cardiomyopathy-propensity score-matched analysis from the Nippon Storm Study","volume":"88","author":"Kondo","year":"2024","journal-title":"Circ J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1161\/CIRCULATIONAHA.109.853689","article-title":"Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial","volume":"120","author":"Packer","year":"2009","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jacc.2020.05.061","article-title":"Long-term outcomes of implantable cardioverter-defibrillator therapy in the SCD-HeFT","volume":"76","author":"Poole","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"B16","article-title":"Boston Scientific Japan K.K. RESONATE ICD Series (package insert\/document no. 97224413-01)","year":""},{"key":"B17","article-title":"Medtronic. Cobalt\u2122 MRI SureScan\u2122 ICD","year":"2024"},{"key":"B18","volume-title":"Guideline for Preparing Cost-Effectiveness Evaluations to the Central Social Insurance Medical Council","year":"2024"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1056\/NEJMoa1211107","article-title":"Reduction in inappropriate therapy and mortality through ICD programming","volume":"367","author":"Moss","year":"2012","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamainternmed.2015.2641","article-title":"Sudden death in patients with cardiac implantable electronic devices","volume":"175","author":"Tseng","year":"2015","journal-title":"JAMA Intern Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/eurheartj\/ehs425","article-title":"A randomized study of remote follow-up of implantable cardioverter defibrillators: safety and efficacy report of the ECOST trial","volume":"34","author":"Guedon-Moreau","year":"2013","journal-title":"Eur Heart J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"131163","DOI":"10.1016\/j.ijcard.2023.131163","article-title":"Heart failure management guided by remote multiparameter monitoring: a meta-analysis","volume":"388","author":"Zito","year":"2023","journal-title":"Int J Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1136\/heartjnl-2017-312546","article-title":"Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention","volume":"104","author":"Barra","year":"2018","journal-title":"Heart"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijcard.2022.11.048","article-title":"Implantable cardioverter defibrillator lead performance: a systematic review and individual patient data meta-analysis","volume":"373","author":"Giacopelli","year":"2023","journal-title":"Int J Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/joa3.12952","article-title":"Improved outcomes of cardiac resynchronization therapy with a defibrillator in systolic heart failure: analysis of the Japan Cardiac Device Treatment Registry database","volume":"40","author":"Yokoshiki","year":"2024","journal-title":"J Arrhythm"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1253\/circj.CJ-16-0196","article-title":"The current status of cardiovascular medicine in Japan\u2014analysis of a large number of health records from a nationwide claim-based database, JROAD-DPC","volume":"80","author":"Yasuda","year":"2016","journal-title":"Circ J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1253\/circrep.CR-24-0130","article-title":"Association of in-hospital cardiac rehabilitation on hospital-associated disability for octogenarian patients with acute myocardial infarction\u2014an insight from the JROAD-DPC database","volume":"7","author":"Kono","year":"2025","journal-title":"Circ Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"B30","year":"2021"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jval.2024.04.016","article-title":"Treatment effect waning assumptions: a review of national institute of health and care excellence technology appraisals","volume":"27","author":"Trigg","year":"2024","journal-title":"Value Health"},{"key":"B32","year":""},{"key":"B33","year":""},{"key":"B34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","article-title":"Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system","volume":"23","author":"Hasegawa","year":"2020","journal-title":"Value Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2147\/VHRM.S369953","article-title":"Cost-effectiveness of cardioverter-defibrillator implantation in Kazakhstan","volume":"18","author":"Begisbayev","year":"2022","journal-title":"Vasc Health Risk Manag"},{"key":"B36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/13696998.2024.2333187","article-title":"Cost effectiveness of implantable cardioverter defibrillators for 1.5 primary prevention of sudden cardiac arrest in China: an analysis from the improve SCA study","volume":"27","author":"Sun","year":"2024","journal-title":"J Med Econ"},{"key":"B37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1161\/CIRCULATIONAHA.105.581884","article-title":"Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the sudden cardiac death in heart failure trial (SCD-HeFT)","volume":"114","author":"Mark","year":"2006","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ahj.2025.07.071","article-title":"PRevention of sudden cardiac death aFter myocardial infarction by defibrillator implantation: design and rationale of the PROFID EHRA randomized clinical trial","volume":"291","author":"Dagres","year":"2026","journal-title":"Am Heart J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/13696998.2021.1877451","article-title":"Comparison of cost-effectiveness of implantable cardioverter defibrillator therapy in patients for primary prevention in Latin America: an analysis using the improve SCA study","volume":"24","author":"Higuera","year":"2021","journal-title":"J Med Econ"},{"key":"B40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ccep.2017.11.014","article-title":"When is it safe not to reimplant an implantable cardioverter defibrillator at the time of battery depletion?","volume":"10","author":"Al-Khatib","year":"2018","journal-title":"Card Electrophysiol Clin"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1744517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:26:09Z","timestamp":1772688369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1744517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2026.1744517"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1744517","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"article-number":"1744517"}}